Cardea Bio

company

About

Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors.

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
$7.50M
Industries
Biotechnology,Information Technology,Manufacturing,Semiconductor
Founded date
Jan 1, 2013
Number Of Employee
11 - 50
Operating Status
Active

Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors. Cardean transistors leverage biocompatible graphene instead of silicon and replace optical signal observations with direct electrical molecular signal analysis. With Cardean transistors, the company and its Innovation Partners can generate streaming multi-omics data to measure real-time biological signals. Cardea is now manufacturing chips at scale and partners have started to significantly expand the amount, type, and quality of biological data they capture by building products that Conduct Biolog.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$7.50M
Cardea Bio has raised a total of $7.50M in funding over 2 rounds. Their latest funding was raised on Sep 17, 2020 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 17, 2020 Series A $7.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Cardea Bio is funded by 1 investors. Agilent Technologies are the most recent investors.
Investor Name Lead Investor Funding Round
Agilent Technologies Series A